ZT-01 is under clinical development by Zucara Therapeutics and currently in Phase II for Nocturnal Hypoglycemia. According to GlobalData, Phase II drugs for Nocturnal Hypoglycemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ZT-01 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZT-01 overview
ZT-01 is under development for the treatment of hypoglycemia in patients with Type 1 diabetes (T1D) and type 2 diabetes. The drug candidate is an octapeptide analog, it is administered through subcutaneous route. It acts by targeting somatostatin receptor type 2 (SSTR2).
Zucara Therapeutics overview
Zucara Therapeutics (Zucara) is a pharmaceutical company that develops novel drug therapies to prevent hypoglycemia in people with diabetes. The company’s technology is used to prevent the dangerous low blood sugar by restoring the body’s ability to counter-regulate hypoglycemia. It is a commercialization agent for academic Institutions in Ontario, Canada. The company also offers therapies to rely of rescue therapies for glucose and glucagon. It works in partnerships with other organizations for the development of novel therapeutic approaches to prevent hypoglycemia. Zucara Therapeutics is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of ZT-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
